PD1-expressing T cell subsets modify the rejection risk in renal transplant patients

Frontiers in Immunology

Volumn 7, Issue APR, 2016, Pages

  Pike, Rebecca ^a   Thomas, Niclas ^a   Workman, Sarita ^a   Ambrose, Lyn ^a   Guzman, David ^a   Sivakumaran, Shivajanani ^a   Johnson, Margaret ^b   Thorburn, Douglas ^b   Harber, Mark ^b   Chain, Benny ^a   Stauss, Hans J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Protein death 1; Rejection; Risk factor; T cells; Transplantation

Indexed keywords

CLINICAL ARTICLE; DEATH; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE STATUS; KIDNEY GRAFT; PHENOTYPE; RISK FACTOR; SUPPORT VECTOR MACHINE; T LYMPHOCYTE SUBPOPULATION;

EID: 84967142298     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00126     Document Type: Article

References (20)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant (2004) 4:378-83. doi: 10.1111/j.1600-6143.2004.00332.x
2. Meier-Kriesche HU, Ojo AO, Hanson JA, Cibrik DM, Punch JD, Leichtman AB, et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation (2000) 70:1098-100. doi:10.1097/00007890-200010150-00018
3. Malheiro J, Tafulo S, Dias L, Martins LS, Fonseca I, Beirao I, et al. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation. Transpl Immunol (2015) 32:66-71. doi:10.1016/j.trim.2015.01.002
4. Chen Y, Tai Q, Hong S, Kong Y, Shang Y, Liang W, et al. Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplantation: a meta-analysis. Transplantation (2012) 94:911-8. doi:10.1097/TP.0b013e31826784ad
5. Roedder S, Sigdel T, Salomonis N, Hsieh S, Dai H, Bestard O, et al. The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med (2014) 11:e1001759. doi:10.1371/journal.pmed.1001759
6. Lee A, Jeong JC, Choi YW, Seok HY, Kim YG, Jeong KH, et al. Validation study of peripheral blood diagnostic test for acute rejection in kidney transplantation. Transplantation (2014) 98:760-5. doi:10.1097/TP.0000000000000138
7. Pisanski T, Shawe-Taylor J. Characterizing graph drawing with eigenvectors. J Chem Inf Comput Sci (2000) 40:567-71. doi:10.1021/ci9900938
8. Platt RW, Leroux BG, Breslow N. Generalized linear mixed models for meta-analysis. Stat Med (1999) 18:643-54. doi:10.1002/(SICI)1097-0258(19990330)18:6<643::AID-SIM76>3.0.CO;2-M
9. Bodenmiller B, Zunder ER, Finck R, Chen TJ, Savig ES, Bruggner RV, et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol (2012) 30:858-67. doi:10.1038/nbt.2317
10. Jaitin DA, Kenigsberg E, Keren-Shaul H, Elefant N, Paul F, Zaretsky I, et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science (2014) 343:776-9. doi:10.1126/science.1247651
11. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 26:677-704. doi:10.1146/annurev.immunol.26.021607.090331
12. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp (2003) 252:67-88;discussion88-91,106-114. doi:10.1002/0470871628.ch6
13. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2006) 439:682-7. doi:10.1038/nature04444
14. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 366:2455-65. doi:10.1056/NEJMoa1200694
15. Gotot J, Gottschalk C, Leopold S, Knolle PA, Yagita H, Kurts C, et al. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proc Natl Acad Sci U S A (2012) 109:10468-73. doi:10.1073/pnas.1201131109
16. Tembhre MK, Parihar AS, Sharma VK, Sharma A, Chattopadhyay P, Gupta S. Alteration in regulatory T cells and programmed cell death 1-expressing regulatory T cells in active generalized vitiligo and their clinical correlation. Br J Dermatol (2015) 172:940-50. doi:10.1111/bjd.13511
17. Franceschini D, Paroli M, Francavilla V, Videtta M, Morrone S, Labbadia G, et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest (2009) 119:551-64. doi:10.1172/JCI36604
18. Brodin P, Jojic V, Gao T, Bhattacharya S, Angel CJ, Furman D, et al. Variation in the human immune system is largely driven by non-heritable influences. Cell (2015) 160:37-47. doi:10.1016/j.cell.2014.12.020
19. Wang YW, Wang Z, Shi BY. Programmed death 1 mRNA in peripheral blood as biomarker of acute renal allograft rejection. Chin Med J (Engl) (2011) 124:674-8
20. Espinosa J, Herr F, Tharp G, Bosinger S, Song M, Farris AB III, et al. CD57 CD4 T cells underlie belatacept-resistant allograft rejection. Am J Transplant (2016) 16:1102-12. doi:10.1111/ajt.13613